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The Role of High-Sensitivity Troponin in 
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A B S T R A C T
The development of assays to detect plasma elevations of cardiac troponins has revo-
lutionized our current clinical practice in the diagnosis and management of acute 
coronary syndromes. Recently new highly sensitive assays for troponin measurement 
have been developed in an effort to detect even minimal elevations suggestive of sub-
clinical injury providing thus the clinicians with additional diagnostic and prognostic 
information. These assays can facilitate an earlier diagnosis of myocardial ischemia or 
necrosis and add substantial prognostic information to improve our risk stratification 
and accordingly our treatment strategy. This increased sensitivity, however, may come 
at the expense of decreased specificity. Nevertheless, accumulating evidence suggests 
that high sensitive troponins, if used appropriately regarding proper timing and evalu-
ation of serial samples and in conjunction with clinical data can improve clinical care 
of patients with acute coronary syndromes.
I n T R o d u C T I o n
The development of assays to detect plasma elevations of cardiac troponins has 
revolutionized our current clinical practice in the diagnosis and management of acute 
coronary syndromes (ACS).1,2 This intracellular protein complex is released in the 
peripheral circulation after myocardial cell damage. Given the fact that both troponin 
T and troponin I are not found in skeletal muscles their release in the blood is thought 
to be highly indicative of myocardial injury.3 Indeed, this particular high diagnostic 
specificity has led to a re-definition of acute myocardial infarction (AMI) based on the 
rise of troponin above the 99th percentile of the upper reference limit.4 Recently new 
highly sensitive assays for troponin measurement have been developed in an effort to 
detect even minimal elevations suggestive of subclinical injury providing thus the clini-
cians with additional diagnostic and prognostic information.5 These assays can facilitate 
an earlier diagnosis of myocardial ischemia or necrosis and add substantial prognostic 
information to improve our risk stratification and accordingly our treatment strategy in 
patients presented with ACS. Studies have shown that of high-sensitivity troponins are 
more accurate in the early diagnosis of AMI.6,7 Moreover, the prognostic information 
offered by the new assays seems to be more robust compared to the old ones.8 This 
increased sensitivity, however, may come at the expense of decreased specificity. Since 
troponin is an indicator of the result but not of the cause of myocardial necrosis, this 
has challenged the widespread use of high sensitivity troponins due to the expected 
increased number of false positive results in the diagnosis of ACS. Nevertheless, ac-
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cumulating evidence suggests that high- sensitivity troponins, 
if used appropriately regarding proper timing and evaluation 
of serial samples and in conjunction with clinical data, can 
improve clinical care of patients with ACS.
C A R d I A C  T R o P o n I n S : 
P A T H o P H Y S I o L o g Y
Cardiac troponins regulate the calcium mediated inter-
action of actin and myosin filaments of muscular cells. The 
troponin complex consists of 3 subunits; troponin C binds cal-
cium, troponin I inhibits the interaction of actin with myosin, 
and troponin T binds the troponin complex to tropomyosin 
facilitating this way muscular contraction. While troponin C 
is expressed in both myocardial and skeletal cells, troponins 
I and T are specific for cardiac muscle. This has led to the 
development of quantitative assays to detect elevations of 
troponin plasma levels as an indicator of myocardial damage.9 
The majority of troponins is bound to the contractile appara-
tus of the myofibril, but approximately 7% of troponin T and 
3-5% of troponin I remain free in the cytoplasm.10 This free 
cytoplasmic troponin is initially released after myocyte damage 
while the myofibril-bound component is released later and 
at a slower pace. This process accounts for the biphasic rise 
of serum troponin after myocardial injury.11,12 In the setting 
of ischemia, transmural myocardial necrosis requires at least 
2-4 hours to occur. Accordingly, an earlier than that diagnosis 
of myocardial injury is not possible with the use of troponin. 
This is the reason that two blood samples are recommended 
to be drawn, one upon presentation and the other 4-6 hours 
later in order to optimize sensitivity and specificity in the 
diagnosis of acute myocardial infarction. Of note, the serum 
levels of troponin I and T remain elevated 4-7 and 10-14 days 
respectively after an AMI occurs. The exact mechanism of 
troponin elimination remains unknown. Although its large 
molecular size seems not to permit renal excretion, recent 
evidence suggests that fragments of troponin T can be renally 
eliminated and this could be a possible explanation for the high 
prevalence of troponinemia in patients with renal failure.13 
Although this simple schema reflects our established knowl-
edge about troponin kinetics, recent evidence suggests a more 
complicated production and turn over. Indeed, measurements 
with the use of the new highly sensitive analytical methods 
have clearly shown that low but detectable troponin levels can 
be traced in healthy individuals.14 Moreover, it has become 
evident that myocardial necrosis is not a prerequisite for the 
elevation of troponin serum levels. Mechanisms unrelated to 
necrotic myocardial damage but possibly related to ischemia 
include apoptosis, release of proteolytic troponin degradation 
products, increased cellular permeability and formation and 
release of membranous blebs.15 The above mechanisms are 
mainly implicated from experimental data, albeit with the use 
of the high sensitive troponin assays some clinical evidence has 
started to emerge. Indeed, beyond normal population, tran-
sient rise and fall in troponin has been observed in marathon 
runners,16 as well as after induction of ischemia.17 
C A R d I A C  T R o P o n I n S :  H I g H - S E n S I T I v E 
A S S A Y S
The development of specific immunoassays to detect 
troponins has led to revolutionary changes in our diagnostic 
and therapeutic strategies for ACS during the last 10-15 years. 
A new universal definition of AMI was introduced. This new 
definition requires the detection of rise and/or fall of cardiac 
troponin above the 99th percentile of the upper reference limit 
together with evidence of ischemia.4 This cutoff point was se-
lected based on studies which had shown that less than 1% of 
the population had detectable troponin which was, moreover, 
associated with the presence of or high risk for cardiovascular 
disease.18 In an effort to further increase precision at these very 
low levels of detection, it was also suggested that instead of the 
99th percentile value the lowest value that an assay showed an 
imprecision (measured as coefficient of variance – CV) 10% 
should be used. Based on that, new generation assays have 
been developed to comply as much as possible with this recom-
mendations.19 These “more sensitive” assays are able to detect 
troponins at much lower concentrations. A clear definition, 
however, of “high sensitivity” was only recently agreed among 
the experts. Thus, high sensitive assays should have a CV<10% 
at the 99th percentile value in the reference population. In 
addition, concentrations below the 99th percentile should be 
detectable above the assays limit of detection in at least >50% 
(and ideally >95%) of healthy individuals in the reference 
population.20 Based on the above, several troponin I and one 
troponin T high-sensitivity assays have been developed (Table 
1). The wide variability in the characteristics of the troponin 
I assays does not permit direct comparisons among them. On 
the other hand, this is not an issue for the single prototype 
highly-sensitive troponin T assay. Beyond this, other analyti-
cal problems for the new high sensitive assays have also been 
underlined. One of them is the definition of the reference 
population. Indeed, the criteria of defining such a population 
have not been agreed upon. Concerns have been raised since 
it has been shown that the precision of these methods can be 
age and sex dependent.21 In addition, biological variability 
which is now easier to detect with this more sensitive assays 
is not known how much can affect their diagnostic accuracy.22 
Indeed, this can be a particular problem when more than one 
values are necessary to be measured. The latter is required 
for diagnostic purposes in the great majority of the clinical 
cases and does not seem to have changed with the use of the 
new assays. Nevertheless, the highly sensitive assays have the 
potential advantage of allowing an earlier, faster and more 
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TABLE 1. Characteristics of the high-sensitivity troponin assays. 
Limits of detection (ng/L) 99th percentile ng/L (Cv) 10% Cv concentration (ng/L)
Hs-cTnI
Roche Elecsys 5.0 14(13%) 13
Hs-cTn-I
Abbot ARCHITECT 1.2 16(5.6%) 3.0
Beckman ACCESS 2 to 3 8.6(10%) 8.6
Mitsubishi Pathfast 8.0 29(5%) 14
Nanosphere 0.2 2.8(9.5%) 0.5
Radiometer 9.5 23(17.7%) 39
Singulex Erenna 0.09 10.1(9.0%) 0.88
Siemens Vista 0.5 9(5.0%) 3
Siemens Centaur 6.0 40(10%) 30
CV: coefficient of variance; HS-TnT: high-sensitivity troponin T; Hs-TnI: high-sensitivity troponin I.
precise diagnosis of myocardial necrosis and ischemia although 
the later remains an issue of debate. 
H I g H - S E n S I T I v I T Y  T R o P o n I n S  I n 
T H E  d I A g n o S I S  o F  A C u T E  C o R o n A R Y 
S Y n d R o M E S
Acute coronary syndromes are a major cause of death and 
disability worldwide.23 Given the fact that only a minority of 
the patients who present in the emergency department with 
chest pain have characteristic electrocardiographic changes, 
cardiac biomarkers play an extremely important role in the 
final diagnosis. Due to their high specificity, the conventionally 
measured troponins have long ago replaced the older biomark-
ers in the diagnosis of ACS, especially of AMI.24 However, due 
to their inability to detect minor troponin elevations during 
the first few hours of the acute event, they still need repeated 
sampling which ends up in prolonged monitoring of the patient 
in the emergency department and delayed treatment of the 
true positive cases. 
The high-sensitivity assays, by detecting also troponin in 
a substantial portion of the healthy population can provide 
clinicians with a more precise cut-off point of normality, 
leaving fewer cases in diagnostic uncertainty. Moreover, it is 
expected that they can lead to an earlier and perhaps ‘’one-
shot’’ diagnosis of AMI. Indeed, with the new assays the 
initial minor elevations of troponin can be detected within 
the first 90 to 180 minutes of the acute event.25 In two large 
prospective trials performed in patients who presented in the 
emergency department, a single measurement of the high 
sensitive assays were more accurate than the conventional 
ones in the diagnosis or the exclusion of AMI within 3 hours 
of the onset of symptoms.6,7 Due to their high specificity these 
assays were also able to reliably rule out AMI on the basis of 
a single measurement (negative predictive value 97-99%). 
More recent studies have confirmed these findings. Aldus et 
al26 showed in a study performed in New Zealand, that high-
sensitivity troponin T was more sensitive than the older assay in 
diagnosing AMI in patients presented with chest pain although 
optimal sensitivity was achieved 4-6 hours after the onset of 
symptoms. Similarly, Ahmed et al27 showed that high sensitive 
troponin T measured in average 4 hours after presentation in 
the emergency department has an excellent negative predictive 
value (96%) for normal subsequent stress test while preserving 
a sensitivity of 90%. 
Beyond their improved diagnostic accuracy, high-sensitivity 
troponins seem to offer also additional prognostic information 
for the patients with ACS. Early generation troponins had 
already shown to be a strong prognostic marker justifying an 
early invasive therapeutic strategy especially in patients with 
non-ST-segment elevation AMI.28,29 In a single center study of 
patients presenting in the emergency department with chest 
pain, a highly sensitive assay outperformed the conventional 
one in predicting cardiovascular mortality at 1-year follow 
up.30 In another study performed in a cohort of 1635 patients 
with suspected ACS, highly sensitive troponin I measured im-
mediately and 2 hours after presentation in conjunction with 
Thrombolysis in Myocardial Infarction (TIMI) risk score ≤1 
could accurately identify patient who had a very low probability 
to sustain a major cardiovascular event in the 30 days of follow 
up.25 More recently, in the LIPID Study (Long-Term Interven-
tion with Pravastatin in Ischaemic Disease) it was shown that 
baseline sensitive troponin T levels was an independent predic-
tor of subsequent cardiovascular death or AMI in patients who 
had suffered an episode of AMI or unstable angina.31 Of note, 
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even small changes of high-sensitivity troponin T (<20%) have 
been associated with increased long-term mortality in patients 
with non-ST-segment elevation AMI.32 
Based on the above it is reasonable to speculate that with 
the new highly sensitive troponins it is expected that our diag-
nostic accuracy in the assessment of patient with a suspected 
ACS will improve both in terms of an earlier and more reliable 
diagnosis, as well as, in defining a very low-risk population who 
can safely be discharged from the emergency department with-
out further work up. Indeed, the recent guidelines recognize 
the superiority of high-sensitivity assays in their potential to 
earlier and more frequently diagnosing AMI. Nevertheless, 
several limitations in their clinical applicability are also been 
underlined.33 
H I g H  S E n S I T I v E  T R o P o n I n S : 
L I M I T A T I o n S
Beyond the fact that high-sensitivity assays have expanded 
the potential role of troponins and its use has been, accord-
ingly, recommended from current guidelines, several issues 
remain open. From a pathopysiological point of view it has 
not been clarified if the minor troponin rises detected with 
the new methods indicate only necrosis or myocardial isch-
emia as well.15 If it is so, an interpretation problem of positive 
results may arise for the clinicians. Nevertheless, this should 
not obscure the clear prognostic role of even minor troponin 
elevations which should dictate an earlier interventional thera-
peutic approach. The issue of cut-off point (99th percentile) 
seems to be haven been agreed upon. However, an impreci-
sion level higher than 10% (until 20%) has been advocated 
by some experts.34 More importantly, the characterisitics of 
the reference population have never been clearly defined. 
Recent studies have shown that different sample populations 
have also different 99th percentile values for the same assay.35 
In addition, these differences are age and sex dependent as 
it was shown in an analysis of the data derived from 3 large 
population-based cohorts.21 Biological variation is another 
not fully clarified issue. This was not relevant with the older 
troponin assays, since they lacked the sensitivity to reliable 
measure troponin in healthy individuals. With the new assays, 
however, specificity can be compromised due to biological 
variation especially in interpreting minor increases. Value dif-
ferences due to biological variation can be detected on a daily, 
weekly or even monthly basis.36 They can even be individual 
specific. Studies have shown that due to this variability short 
term changes up to 85% and long term changes up to 315% 
would be necessary to assure an abnormal highly-sensitive 
troponin elevation.37 
To overcome this problem serial measurements in the case 
of an initial positive value are necessary. However, even the 
level of changes in serial measurement as well as the time of 
repeated sampling to verify the diagnosis of AMI remain also 
debatable issues. The proposed changes among serial samples 
have been ranging from 20-200%.38,39 It is nevertheless obvi-
ous, that the higher the initial troponin the lower the level of 
change required to consider the test results compatible with 
myocardial necrosis. On the other hand, both timing of re-
peated sampling and interpretation of the results have not also 
been standardized. The current guidelines suggest measuring 
one sample upon presentation and one sample 3 hours later. 
Current evidence suggests that this approach has a sensitivity 
and negative predictive value of 100%.40 However, others have 
shown that a 6-hour period is required to firmly establish the 
diagnosis of AMI.41 Regarding the assessment of the changing 
pattern of troponins, general consensus is also lacking. Others 
have advocated the percentage change, the so-called delta tro-
ponin,42 while others have shown that absolute changes are of 
superior diagnostic value compared to the relative changes.38 
Finally, the issue of specificity compromise due to increased 
sensitivity is certainly not a negligible one. Since troponin el-
evation indicates the result (myocardial necrosis or ischemia) 
but not the case of it, there is a long catalog of conditions other 
than acute coronary thrombosis which have been associated 
with troponinemia (Table 2).43 With the new sensitive assays 
the percent of non-coronary associated troponin elevation can 
dramatically increase. For example, patients on hemodialysis 
have shown minor troponin elevations at a percentage ap-
proximating 100%.44 
TABLE 2. Non-coronary causes of high-sensitivity troponin 
elevation
Cardiac Causes non-Cardiac Causes
Heart Failure Renal Failure
Myocarditis / Pericarditis Sepsis
Stress-induced Cardiomyopathy Pulmonary Hypertension / 
Embolism
Post uncomplicated PCI Drug Toxicity
Post uncomplicated CABG Hypothyroidism
Myocardial Contusion Stroke / Intracerebral 
Hemorrhage
Post uncomplicated 
Radiofrequency Ablation
Rhabdomyolysis
Tachyarrhythmias Stenuous Exercise
Hypotension / Shock
Aortic Dissection
CABG = coronary artery bypass grafting; PCI = percutaneous coronary 
intervention
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C o n C L u S I o n S
The new high-sensitivity assays for troponin detection of-
fer the opportunity for a more rapid and accurate diagnosis 
of ACS leading this way to a potential increase in the number 
of patients who will benefit from an early invasive procedure. 
Moreover, a rapid “rule-out” for patients presenting with 
chest pain in the emergency department seems feasible. 
Nevertheless, studies to determine if incorporation of these 
new methods in clinical practice will improve outcome of 
the patients, are still lacking. Moreover, concerns have been 
raised for the possibility of over-diagnosing AMI in patients in 
whom other mechanisms than myocardial necrosis or ischemia 
are responsible for troponin elevation. This underscores the 
importance of using serial measurement of the high-sensitivity 
troponin assays, when they become widely available, and always 
in conjunction with a detailed clinical assessment particularly 
for those patients who now will have positive results while 
they would had been “ruled-out” with the conventional (less 
sensitive) assays. 
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